Asana Medical, Inc. to Present as Innovation Challenge Finalist at RESI Boston Conference 2017

MIAMI LAKES, FL – September 11, 2017 — Asana Medical, Inc., (“Asana,” the “Company”), a regenerative medicine company developing a novel treatment for Ulcerative Colitis, is pleased to announce that it has been selected as an Innovation Challenge Finalist and will present at the RESI Conference in Boston, Massachusetts on Tuesday, September 26th, 2017.  The RESI (Redefining Early Stage Investments) Conference is an investor conference for early-stage life science companies, and is being held at the Boston Marriott Copley Place.

“We are looking forward to attending RESI and introducing our regenerative medicine technology to the attendees of the conference on September 26th,” stated Brian Andersen, Chief Business Officer of Asana Medical.  “In addition, we’ll be announcing some exciting news prior to our Boston appearance that will further define our corporate mission and identity,” added Andersen.

Asana Medical is currently developing a drug-free, non-surgical solution for the millions of sufferers of Ulcerative Colitis (“UC”).  The Company’s proprietary product, Extra-Cellular Matrix Hydrogel (“ECMH”) has shown significant regenerative properties during pre-clinical trials conducted at the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.  The trial’s data published in the Journal of Crohn’s and Colitis underscored ECMH’s mucosal healing properties in a widely accepted animal model by establishing rapid tissue regeneration and restoration of the barrier function in the animal’s colon, and reduction in clinical symptoms.

Asana’s initial target market is UC, a debilitating disease affecting more than 1.8 million people worldwide. Publicly available forecasts estimated pharmaceutical sales approved to treat UC exceeded $4.0 billion in 2012 and are forecasted to grow to $6.8 billion by 2022.  UC is characterized by recurring episodes of inflammation of the innermost layer of the colon, i.e. the mucosa.  Typical symptoms include pain, chronic diarrhea, bleeding, and urgency to use the restroom. More severe symptoms include malnutrition and dehydration. An increased risk of colon cancer has also been clinically documented.  There is no cure, but Asana believes that its ECMH technology could disrupt the treatment paradigm for UC and reduce the need for major surgery.  “We are excited at the prospects that ECMH will have a profound impact on the lives of patients suffering from UC. We continue to advance the development of ECMH and anticipate commencement of our clinical trials in early 2018,” stated Andersen.

If you are attending the RESI Conference, or will be in Boston on September 26th, and would like to schedule a one-on-one meeting to learn more about Asana Medical, Inc., please email Mr. Brian Andersen at



The RESI Innovation Challenge consists of the 30 most innovative companies that are hand-selected by Life Science Nation’s internal scientific review board.   As part of the RESI Innovation Challenge, companies present their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their business model and products in a poster format.  Unlike traditional 5- to 15-minute presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to speak directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.


Asana Medical, Inc. is a regenerative medicine company developing a tissue engineered therapy for the treatment of Ulcerative Colitis (UC).   The Company’s product ECMH, a novel application of a proven technology, will be a first-in-class therapy for patients suffering from Ulcerative Colitis. This therapy will be positioned to compete in a multi-billion-dollar market dominated by biologic and drug therapies that can have significant side effects. Additionally, 20-30% of patients do not benefit from these therapies and have no alternative except colon removal surgery. Asana has an experienced management team, strong patent protection, world-class advisors in business and medicine, and compelling preclinical proof-of-concept data.  For more information, visit

Keep up-to-date on all of Asana’s news and developments, join our online communities:
Asana Medical – Facebook

Asana Medical – Twitter
Asana Medical – LinkedIn



Gerard Coombs
Executive Vice President

Asana Medical, Inc.
6135 NW 167 Street, Suite E15
Miami Lakes, FL 33015

Tel: (844) 432-7262 Ext 102